Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
AbCellera Biologics Inc. (ABCL) had Normalized Income after Taxes of $-8.95M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$44.85M |
|
$-8.95M |
|
-- |
|
$44.85M |
|
$73.43M |
|
$-28.58M |
|
$9.08M |
|
$-19.50M |
|
$-19.50M |
|
$-8.95M |
|
$-8.95M |
|
$-8.95M |
|
|
Normalized Income after Taxes |
$-8.95M |
$-28.58M |
|
$-20.66M |
|
298.71M |
|
298.71M |
|
$-0.03 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$728.23M |
|
$428.00M |
|
$628.72M |
|
$1.36B |
|
$64.31M |
|
-- |
|
$325.74M |
|
$390.05M |
|
$966.90M |
|
$880.72M |
|
$966.90M |
|
300.60M |
|
| Cash Flow Statement Financials | |
$-131.29M |
|
$87.75M |
|
$14.08M |
|
$183.62M |
|
$155.25M |
|
$-28.37M |
|
$55.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-63.72% |
|
-63.72% |
|
-- |
|
-43.47% |
|
-19.94% |
|
$-174.07M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
0.77 |
|
116.97 |
|
-0.93% |
|
-1.02% |
|
-0.66% |
|
-0.93% |
|
$3.22 |
|
$-0.58 |
|
$-0.44 |
|